Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 7/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086084 | 0.89 | MAPT (0.49) | MAPTKDM4EPOLBCETPTHRB | |
| SCHEMBL6084729 | 0.88 | MAPT (0.60) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6084979 | 0.86 | MAPT (0.57) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6083652 | 0.86 | MAPT (0.68) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6085050 | 0.86 | MAPT (0.60) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6087376 | 0.85 | PTGS2 (0.51) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6086246 | 0.83 | TP53 (0.56) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6084109 | 0.82 | PTGS2 (0.64) | MAPTKDM4EPTGS2THRBRXFP1 | |
| SCHEMBL6084901 | 0.82 | POLB (0.62) | MAPTKDM4EPOLBNPSR1CETP | |
| SCHEMBL6085991 | 0.81 | TP53 (0.55) | MAPTKDM4EPOLBNPSR1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | claimed |
| US-7105535-B2 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2006-09-12 | — | — | US | disclosed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | disclosed |
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180881-A1 | Oxazolyl-pyrazole derivatives as kinase inhibitors | MAP3K15, MAP3K20, MAP3K3 | MAPT 801/4885KDM4E 1175/4885POLB 1679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.